Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 6

See more details

Referenced in 2 patents
48 readers on Mendeley
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI116904

One systemic administration of transforming growth factor-beta 1 reverses age- or glucocorticoid-impaired wound healing.

L S Beck, L DeGuzman, W P Lee, Y Xu, M W Siegel, and E P Amento

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by Beck, L. in: PubMed | Google Scholar

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by DeGuzman, L. in: PubMed | Google Scholar

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by Lee, W. in: PubMed | Google Scholar

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by Xu, Y. in: PubMed | Google Scholar

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by Siegel, M. in: PubMed | Google Scholar

Department of Developmental Biology, Genentech Inc., South San Francisco, California 94080.

Find articles by Amento, E. in: PubMed | Google Scholar

Published December 1, 1993 - More info

Published in Volume 92, Issue 6 on December 1, 1993
J Clin Invest. 1993;92(6):2841–2849. https://doi.org/10.1172/JCI116904.
© 1993 The American Society for Clinical Investigation
Published December 1, 1993 - Version history
View PDF
Abstract

The role of intravenously administered recombinant human transforming growth factor-beta 1 (rhTGF-beta 1) on the healing of incisional wounds in rats with impaired healing due to age or glucocorticoid administration was investigated. The administration of methylprednisolone to young adult rats decreased wound breaking strength to 50% of normal control. Breaking strength of incisional wounds from 19-mo-old rats was decreased approximately 27% compared with wounds from normal healing young adult rats. A single intravenous administration of rhTGF-beta 1 (100 or 500 micrograms/kg) increased wound breaking strength from old rats or young adult rats with glucocorticoid-induced impaired healing to levels similar to normal healing control animals when determined 7 d after injury. Even though the circulating half-life of systemically administered rhTGF-beta 1 is < 5 min, a sustained stimulatory effect on extracellular matrix secretion was evident in glucocorticoid-impaired rats when rhTGF-beta 1 was administered at the time of wounding, 4 h after wounding, or even 24 h before wounding. These observations indicate a previously unrecognized potential for the active form of TGF-beta 1 to profoundly influence the wound healing cascade after brief systemic exposure.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 2841
page 2841
icon of scanned page 2842
page 2842
icon of scanned page 2843
page 2843
icon of scanned page 2844
page 2844
icon of scanned page 2845
page 2845
icon of scanned page 2846
page 2846
icon of scanned page 2847
page 2847
icon of scanned page 2848
page 2848
icon of scanned page 2849
page 2849
Version history
  • Version 1 (December 1, 1993): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 6
  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 2 patents
48 readers on Mendeley
See more details